CLYMClimb Bio Inc
What is the market doing?
Rangebound. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Choppy, but holding above its 200-day average. Oversold (RSI 19). Price is +10% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CLYM is trading
Climb Bio Inc is +558% over the past year while the S&P 500 is +18%: 540 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +9.7%
vs 200-day average · close to trend
- RSI (14)
- 19
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 39%
Below its 52-week high
Details›
- Last close2026-10-08
- $10.86
- 1 monthS&P 500 +1.6%
- −28%
- 1 yearS&P 500 +18%
- +558%
- 5 yearsS&P 500 +86%
- −40%
- vs 50-day average$13.93
- −22%
- 52-week high
- $17.83
- 52-week low
- $1.64
- Annualised volatility
- 89%
| Year | Return |
|---|---|
| 2026 (year to date) | +172% |
| 2025 | +122% |
| 2024 | −33% |
| 2023 | −26% |
| 2022 | −65% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 2 of 5 | −1.2% |
| Feb | 5 | 3 of 5 | +8.9% |
| Mar | 5 | 1 of 5 | −9.0% |
| Apr | 5 | 4 of 5 | +29% |
| May | 5 | 3 of 5 | +6.9% |
| Jun | 5 | 2 of 5 | −1.8% |
| Jul | 5 | 3 of 5 | +4.3% |
| Aug | 5 | 2 of 5 | +11% |
| Sep | 6 | 1 of 6 | −13% |
| Oct | 6 | 2 of 6 | −5.0% |
| Nov | 5 | 0 of 5 | −13% |
| Dec | 5 | 3 of 5 | +18% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.